A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co.

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...

MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...